Potential role of α-synuclein in neurodegeneration: Studies in a rat animal model

Journal of Neurochemistry

Volumn 122, Issue 4, 2012, Pages 812-822

  Stoica, George ^a   Lungu, Gina ^a   Bjorklund, Nicole L ^b   Taglialatela, Giulio ^b   Zhang, Xing ^c   Chiu, Veronica ^c   Hill, Herbert H ^c   Schenk, James O ^c   Murray, Ian ^d  

^a TEXAS A AND M UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

synuclein; dopamine; neurodegeneration; Parkinson's; rat model

Indexed keywords

ALPHA SYNUCLEIN; CYTOKINE; DOPAMINE; DOPAMINE RECEPTOR; TYROSINE 3 MONOOXYGENASE;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BASAL GANGLION; BRAIN STEM; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; GLIOSIS; HISTOPATHOLOGY; IMMUNOREACTIVITY; ION MOBILITY SPECTROMETRY; MALE; MESENCEPHALON; MOTOR DYSFUNCTION; NERVE DEGENERATION; NITROSYLATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; SUBSTANTIA NIGRA; TRANSMISSION ELECTRON MICROSCOPY;

ALPHA-SYNUCLEIN; ANIMALS; BASAL GANGLIA; BLOTTING, WESTERN; CORPUS STRIATUM; CYTOKINES; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; GLIOSIS; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MESENCEPHALON; MICROSCOPY, ELECTRON, TRANSMISSION; NEURAL PATHWAYS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; RATTUS;

EID: 84864144621     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2012.07805.x     Document Type: Article

References (40)

1. Baptista M. J., O'Farrell C., Daya S., Ahmad R., Miller D. W., Hardy J., Farrer M. J., and, Cookson M. R., (2003) Co-ordinate transcriptional regulation of dopamine synthesis genes by α-synuclein in human neuroblastoma cell lines. J. Neurochem. 85, 957-968.
2. Bartels T., Choi J. G., and, Selkoe D. J., (2011) α-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 14, 107-110.
3. Braak H., Bohl J. R., Muller C. M., Rub U., de Vos R. A., and, Del Tredici K., (2005) The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 21, 2042-2051.
4. Brown D. R., (2010) Oligomeric α-synuclein and its role in neuronal death. IUBMB Life 62, 334-339.
5. Byers B., Cord B., Nguyen H. N., Schule B., Fenno L., Lee P. C., Deisseroth K., Langston J. W., Pera R. R., and, Palmer T. D,. (2011) SNCA triplication Parkinson's patient's iPCP-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PlosONE 6, e26159.
6. Chartier-Harlin M. C., Kachergus J., Roumier C., et al. (2004) α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169.
7. Cookson R. M., and, Van der Brug M., (2008) Cell systems and the toxic mechanism(s) of α-synuclein. Exp. Neurol. 209, 5-11.
8. da Costa C. A., Ancolio K., and, Checler F., (2000) Wild-type but not Parkinson's disease-related Ala-53 → Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24065-24069.
9. Fauvet B., Mbefo M. K., Fares M.-B., et al. (2012) α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomers. J. Biol. Chem. 287, 15345-15364.
10. Griffin W., Sue T., Ling L., Yuekui L., Mrak R. E., and, Barger S. W., (2006) Interleukin-1 mediates Alzheimer and Lewy body pathologies. J. Neuroinflammation 3, 1-9.
11. Ibáñez P., Bonnet A. M., Débarges B., Lohmann E., Tison F., Pollak P., Agid Y., Dürr A., and, Brice A., (2004) Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169-1171.
12. Jellinger K. A., (2009) A critical evaluation of current staging of α-synuclein pathology in Lewy bodies disorders. Biochim. Biophys. Acta 179, 730-740.
13. Kaplan K., Dwivedi P., Davidson S., Yang Q., Tso P., Siems W., and, Hill H. H., Jr, (2009) Monitoring dynamic changes in lymph metabolome of fasting and fed rats by electrospray ionization-ion mobility mass spectrometry (ESI-IMMS). Anal. Chem. 8, 7944-7953.
14. Kingsbury A. E., Bandopadhyay R., Silveira-Moriyama L., Ayling H., Kallis C., Sterlacci W., Maeir H., Poewe W., and, Lees A. J., (2010) Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov. Disord. 2, 2508-2515.
15. Kramer L. M., and, Schulz-Schaeffer W. J., (2007) Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27, 1405-1410.
16. Kramer L. M., Behrens C., and, Schulz-Schaeffer W. J., (2008) Selective detection, quantification, and subcellular location of α-synuclein aggregates with a protein aggregate filtration assay. Biotechniques 44, 403-411.
17. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L., and, Riess O., (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
18. Lee S. J., (2008) Origin and effects of extracellular α-synuclein: implications in Parkinson's disease. J. Mol. Neurosci. 34, 17-32.
19. Lucking C. B., and, Brice C., (2000) α-synuclein and Parkinson's disease. Cell. Mol. Life Sci. 57, 1894-1908.
20. Lungu G., Stoica G., and, Wong P. K. Y., (2008) Down-regulation of Jab1, HIF-1α, and VEGF by Molony murine leukemia virus-ts1 infection: a possible cause of neurodegeneration. J. Neurovirol. 1, 239-51.
21. Maries E., Dass B., Collier T. J., Kordower J. H., and, Steece-Collier K., (2003) The role of α-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 4, 727-738.
22. Martin Z. S., Neugebauer V., Dineley K. T., Kayed R., Zhang W., Reese L. C., and, Taglialatela G., (2012) α-synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism:relevance to human synucleopathic disease. J. Neurochem. 120, 440-452.
23. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and, Mucke L., (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implication for neurodegenerative disorders. Science 287, 18.
24. McGeer P. L., and, McGeer E. G., (2008) Glial reaction in Parkinson's disease. Rev. Mov. Dis. 23, 474-483.
25. Melrose H. L., Licoln S. J., Tyndall G. M., and, Farrer M. J., (2006) Parkinson's disease: a rethink of rodent models. Exp. Brain Res. 17, 196-204.
26. Michael J. V., and, Peter Jr T. L., (2003) Zeroing in the pathogenic form of α-syn and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 4, 7871-7878.
27. Norris E. H., Giasson I. B., and, Virginia M. Y. L., (2004) A-Synuclein: normal function and role in neurodegenerative diseases. Curr. Top. Dev. Biol. 60, 17-54.
28. Paxinos G., and, Watson C,. (2006) The Rat Brain in Stereotaxic Coordinates, AP, San Diego.
29. Perez R. G., Waymire J. C., Lin E., Liu J. J., Guo F., and, Zigmond M. J., (2002) A role of α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090-3099.
30. Polymeropoulos M. H., Lavedan C., Leroy E., et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 27, 2045-2047.
31. Shavali S., Combs C. K., and, Ebadi M., (2006) Reactive macrophages increase oxidative stress and α-synuclein nitration during death of dopaminergic neuronal cells in co-culture: relevance to Parkinson's disease. Neurochem. Res. 24, 85-94.
32. Singleton A. B., Farrer M., Johnson J., Singleton A., Hague S., et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
33. Stoica G., Illanes O., Tasca S., and, Wong P. K. Y., (1993) Temporal central and peripheral nervous system changes induced by a paralytogenic mutant Moloney murine leukemia virus. Lab. Invest. 69, 724-735.
34. Surguchov A., (2008) Molecular and cellular biology of Synucleins. Int. Rev. Cell Mol. Biol. 270, 225-317.
35. Volpicelli-Daley L. A., Luk K. C., Patel T. P., Tanik S. A., Riddle D. M., Stieber A., Meaney D. F., Trojanowski J. Q., and, Lee V. M.-Y., (2011) Exogenous α-Synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71.
36. Wang W., Perovic I., Chittuluru J., et al. (2011) A soluble α-synuclein construct forms a dynamic tetramer. Proc. Natl Acad. Sci. 108, 17797-17802.
37. Waters C. H., and, Miller C. A., (1994) Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann. Neurol. 35, 59-64.
38. Zaja-Milatovic S., Keen C. D., Montine K. S., Leverenz J. B., Tsuang D., and, Montine T. J., (2006) Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology 66, 1591-1593.
39. Zarranz J. J., Alegre J., Gomez-Esteban J. C., Lezcano E, and, Ross R., (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.
40. Zhang W., Wang T., and, Pei Z., (2005) Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinsons's disease. FASEB J. 19, 533-542.